Fluvoxamine, a selective serotonin reuptake inhibitor, and 5-HT 2C receptor inactivation induce appetite-suppressing effects in mice via 5-HT1B receptors

Katsunori Nonogaki, Kana Nozue, Yukiko Takahashi, Nobuyuki Yamashita, Shuichi Hiraoka, Hiroaki Kumano, Tomifusa Kuboki, Yohsitomo Oka

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Serotonin (5-hydroxytryptamine; 5-HT) 2C receptors and the downstream melanocortin pathway are suggested to mediate the appetite-suppressing effects of 5-HT drugs such as m-chlorophenylpiperazine (mCPP) and fenfluramine. Here, we report that fluvoxamine (3-30 mg/kg), a selective serotonin reuptake inhibitor (SSRI), in the presence of SB 242084 (1-2 mg/kg), a selective 5-HT2C receptor antagonist, exerts appetite-suppressing effects while fluvoxamine or SB 242084 alone has no effect. The appetite-suppressing effects were attenuated in the presence of SB 224289 (5 mg/kg), a selective 5-HT1B receptor antagonist. Moreover, CP 94253 (5-10 mg/kg), a selective 5-HT1B receptor agonist, exerted appetite-suppressing effects and significantly increased hypothalamic pro-opiomelanocortin (POMC) and cocaine- and amphetamine-regulated transcript (CART) gene expression and decreased hypothalamic orexin gene expression. These results suggest that fluvoxamine and inactivation of 5-HT2C receptors exert feeding suppression through activation of 5-HT1B receptors, and that 5-HT1C receptors up-regulate hypothalamic POMC and CART gene expression and down-regulate hypothalamic orexin gene expression in mice.

Original languageEnglish
Pages (from-to)675-681
Number of pages7
JournalInternational Journal of Neuropsychopharmacology
Volume10
Issue number5
DOIs
Publication statusPublished - 2007
Externally publishedYes

Fingerprint

Receptor, Serotonin, 5-HT2C
Receptor, Serotonin, 5-HT1B
Fluvoxamine
Serotonin Uptake Inhibitors
Appetite
Gene Expression
Pro-Opiomelanocortin
Serotonin
Amphetamine
Cocaine
Serotonin 5-HT1 Receptor Antagonists
Melanocortins
Serotonin 5-HT1 Receptor Agonists
Serotonin 5-HT2 Receptor Antagonists
Fenfluramine
Up-Regulation
Down-Regulation
Pharmaceutical Preparations
6-chloro-5-methyl-1-((2-(2-methylpyrid-3-yloxy)pyrid-5-yl)carbamoyl)indoline

Keywords

  • 5-HT receptor
  • 5-HT receptor
  • Appetite
  • POMC
  • SSRI

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Neuropsychology and Physiological Psychology
  • Neuroscience(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Fluvoxamine, a selective serotonin reuptake inhibitor, and 5-HT 2C receptor inactivation induce appetite-suppressing effects in mice via 5-HT1B receptors. / Nonogaki, Katsunori; Nozue, Kana; Takahashi, Yukiko; Yamashita, Nobuyuki; Hiraoka, Shuichi; Kumano, Hiroaki; Kuboki, Tomifusa; Oka, Yohsitomo.

In: International Journal of Neuropsychopharmacology, Vol. 10, No. 5, 2007, p. 675-681.

Research output: Contribution to journalArticle

Nonogaki, Katsunori ; Nozue, Kana ; Takahashi, Yukiko ; Yamashita, Nobuyuki ; Hiraoka, Shuichi ; Kumano, Hiroaki ; Kuboki, Tomifusa ; Oka, Yohsitomo. / Fluvoxamine, a selective serotonin reuptake inhibitor, and 5-HT 2C receptor inactivation induce appetite-suppressing effects in mice via 5-HT1B receptors. In: International Journal of Neuropsychopharmacology. 2007 ; Vol. 10, No. 5. pp. 675-681.
@article{d0944c0dd32d477b983a7d02123c238d,
title = "Fluvoxamine, a selective serotonin reuptake inhibitor, and 5-HT 2C receptor inactivation induce appetite-suppressing effects in mice via 5-HT1B receptors",
abstract = "Serotonin (5-hydroxytryptamine; 5-HT) 2C receptors and the downstream melanocortin pathway are suggested to mediate the appetite-suppressing effects of 5-HT drugs such as m-chlorophenylpiperazine (mCPP) and fenfluramine. Here, we report that fluvoxamine (3-30 mg/kg), a selective serotonin reuptake inhibitor (SSRI), in the presence of SB 242084 (1-2 mg/kg), a selective 5-HT2C receptor antagonist, exerts appetite-suppressing effects while fluvoxamine or SB 242084 alone has no effect. The appetite-suppressing effects were attenuated in the presence of SB 224289 (5 mg/kg), a selective 5-HT1B receptor antagonist. Moreover, CP 94253 (5-10 mg/kg), a selective 5-HT1B receptor agonist, exerted appetite-suppressing effects and significantly increased hypothalamic pro-opiomelanocortin (POMC) and cocaine- and amphetamine-regulated transcript (CART) gene expression and decreased hypothalamic orexin gene expression. These results suggest that fluvoxamine and inactivation of 5-HT2C receptors exert feeding suppression through activation of 5-HT1B receptors, and that 5-HT1C receptors up-regulate hypothalamic POMC and CART gene expression and down-regulate hypothalamic orexin gene expression in mice.",
keywords = "5-HT receptor, 5-HT receptor, Appetite, POMC, SSRI",
author = "Katsunori Nonogaki and Kana Nozue and Yukiko Takahashi and Nobuyuki Yamashita and Shuichi Hiraoka and Hiroaki Kumano and Tomifusa Kuboki and Yohsitomo Oka",
year = "2007",
doi = "10.1017/S1461145706007206",
language = "English",
volume = "10",
pages = "675--681",
journal = "International Journal of Neuropsychopharmacology",
issn = "1461-1457",
publisher = "Cambridge University Press",
number = "5",

}

TY - JOUR

T1 - Fluvoxamine, a selective serotonin reuptake inhibitor, and 5-HT 2C receptor inactivation induce appetite-suppressing effects in mice via 5-HT1B receptors

AU - Nonogaki, Katsunori

AU - Nozue, Kana

AU - Takahashi, Yukiko

AU - Yamashita, Nobuyuki

AU - Hiraoka, Shuichi

AU - Kumano, Hiroaki

AU - Kuboki, Tomifusa

AU - Oka, Yohsitomo

PY - 2007

Y1 - 2007

N2 - Serotonin (5-hydroxytryptamine; 5-HT) 2C receptors and the downstream melanocortin pathway are suggested to mediate the appetite-suppressing effects of 5-HT drugs such as m-chlorophenylpiperazine (mCPP) and fenfluramine. Here, we report that fluvoxamine (3-30 mg/kg), a selective serotonin reuptake inhibitor (SSRI), in the presence of SB 242084 (1-2 mg/kg), a selective 5-HT2C receptor antagonist, exerts appetite-suppressing effects while fluvoxamine or SB 242084 alone has no effect. The appetite-suppressing effects were attenuated in the presence of SB 224289 (5 mg/kg), a selective 5-HT1B receptor antagonist. Moreover, CP 94253 (5-10 mg/kg), a selective 5-HT1B receptor agonist, exerted appetite-suppressing effects and significantly increased hypothalamic pro-opiomelanocortin (POMC) and cocaine- and amphetamine-regulated transcript (CART) gene expression and decreased hypothalamic orexin gene expression. These results suggest that fluvoxamine and inactivation of 5-HT2C receptors exert feeding suppression through activation of 5-HT1B receptors, and that 5-HT1C receptors up-regulate hypothalamic POMC and CART gene expression and down-regulate hypothalamic orexin gene expression in mice.

AB - Serotonin (5-hydroxytryptamine; 5-HT) 2C receptors and the downstream melanocortin pathway are suggested to mediate the appetite-suppressing effects of 5-HT drugs such as m-chlorophenylpiperazine (mCPP) and fenfluramine. Here, we report that fluvoxamine (3-30 mg/kg), a selective serotonin reuptake inhibitor (SSRI), in the presence of SB 242084 (1-2 mg/kg), a selective 5-HT2C receptor antagonist, exerts appetite-suppressing effects while fluvoxamine or SB 242084 alone has no effect. The appetite-suppressing effects were attenuated in the presence of SB 224289 (5 mg/kg), a selective 5-HT1B receptor antagonist. Moreover, CP 94253 (5-10 mg/kg), a selective 5-HT1B receptor agonist, exerted appetite-suppressing effects and significantly increased hypothalamic pro-opiomelanocortin (POMC) and cocaine- and amphetamine-regulated transcript (CART) gene expression and decreased hypothalamic orexin gene expression. These results suggest that fluvoxamine and inactivation of 5-HT2C receptors exert feeding suppression through activation of 5-HT1B receptors, and that 5-HT1C receptors up-regulate hypothalamic POMC and CART gene expression and down-regulate hypothalamic orexin gene expression in mice.

KW - 5-HT receptor

KW - 5-HT receptor

KW - Appetite

KW - POMC

KW - SSRI

UR - http://www.scopus.com/inward/record.url?scp=34948867184&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34948867184&partnerID=8YFLogxK

U2 - 10.1017/S1461145706007206

DO - 10.1017/S1461145706007206

M3 - Article

C2 - 16959056

AN - SCOPUS:34948867184

VL - 10

SP - 675

EP - 681

JO - International Journal of Neuropsychopharmacology

JF - International Journal of Neuropsychopharmacology

SN - 1461-1457

IS - 5

ER -